Chen Even - DiaSorin SpA Chief Commercial Officer and Executive Director
| DSRLF Stock | USD 109.60 9.34 9.32% |
Director
Dr. Chen Manachem Even serves as Executive Director, Chief Commercial Officer of Diasorin S.p.A. He is Chief Commercial Officer since January 1, 2016. He was in the Company Board of Directors since March 26, 2007. Additionally, he serves at Glycominds Ltd., CID Investments Srl, and others. He graduated in Information Science in 1989. In 1995, he received a Doctorate of Medicine degree in Virology and Immunology Research from the School of Medicine of University of Minnesota. He serves as Director of Glycominds LTD, DiaSorin Ltd, CID SpA, DiaSorin SANV, DiaSorin INC, Diasorin Ltd, DiaSorin Iberia SA, DiaSorin Mexico SA de CV, DiaSorin Australia Pty, DiaSorin Diagnostics Ireland Limited, DiaSorin I.N.UK and DiaSorin Ireland Limited. since 2016.
| Age | 60 |
| Tenure | 9 years |
| Professional Marks | Ph.D |
| Phone | 39 01 614871 |
| Web | https://diasoringroup.com |
DiaSorin SpA Management Efficiency
The company has return on total asset (ROA) of 0.0902 % which means that it generated a profit of $0.0902 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.198 %, meaning that it generated $0.198 on every $100 dollars invested by stockholders. DiaSorin SpA's management efficiency ratios could be used to measure how well DiaSorin SpA manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Hans Bishop | Agilent Technologies | 56 | |
| Lars Sorensen | Thermo Fisher Scientific | 67 | |
| Teri ListStoll | Danaher | 58 | |
| Debora Spar | Thermo Fisher Scientific | 56 | |
| Colleen Goggins | IQVIA Holdings | 66 | |
| Thomas Salice | Mettler Toledo International | 61 | |
| George Llado | Charles River Laboratories | 55 | |
| Richard Francis | Mettler Toledo International | 52 | |
| Elias Zerhouni | Danaher | 69 | |
| Dion Weisler | Thermo Fisher Scientific | 53 | |
| Judy Lewent | Thermo Fisher Scientific | 71 | |
| Dow Wilson | Agilent Technologies | 61 | |
| A Sanders | Danaher | 58 | |
| James Fasano | IQVIA Holdings | 50 | |
| Deborah Kochevar | Charles River Laboratories | 64 | |
| Mala Anand | Agilent Technologies | 53 | |
| Elaine Ullian | Thermo Fisher Scientific | 70 | |
| Walter Lohr | Danaher | 77 | |
| JeanPaul Mangeolle | Charles River Laboratories | 57 | |
| Michael Berendt | Waters | 71 | |
| Gary Hendrickson | Waters | 64 | |
Management Performance
| Return On Equity | 0.2 | |||
| Return On Asset | 0.0902 |
DiaSorin SpA Leadership Team
Elected by the shareholders, the DiaSorin SpA's board of directors comprises two types of representatives: DiaSorin SpA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DiaSorin. The board's role is to monitor DiaSorin SpA's management team and ensure that shareholders' interests are well served. DiaSorin SpA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DiaSorin SpA's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Fabrizio Bonelli, Chief Officer | ||
| Carlo Rosa, CEO, General Manager and Executive Director | ||
| Piergiorgio Pedron, Senior Corporate VP and CFO | ||
| Ulisse Spada, Mang Department | ||
| Angelo Rago, Pres Corp | ||
| Stefano Ronchi, Sr. Corporate VP of HR | ||
| Ugo Gay, Sr Operations | ||
| Chen Even, Chief Commercial Officer and Executive Director | ||
| Riccardo Fava, Director of Investor Relations and Corporate Communication |
DiaSorin Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is DiaSorin SpA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.2 | |||
| Return On Asset | 0.0902 | |||
| Profit Margin | 0.20 % | |||
| Operating Margin | 0.29 % | |||
| Current Valuation | 8.64 B | |||
| Shares Outstanding | 53.84 M | |||
| Shares Owned By Insiders | 57.50 % | |||
| Shares Owned By Institutions | 22.36 % | |||
| Price To Earning | 26.36 X | |||
| Price To Book | 4.73 X |
Currently Active Assets on Macroaxis
Other Information on Investing in DiaSorin Pink Sheet
DiaSorin SpA financial ratios help investors to determine whether DiaSorin Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in DiaSorin with respect to the benefits of owning DiaSorin SpA security.